AgeX Therapeutics Top Management

AGEDelisted Stock  USD 0.74  0.01  1.37%   
AgeX Therapeutics employs about 4 people. The company is managed by 13 executives with a total tenure of roughly 35 years, averaging almost 2.0 years of service per executive, having 0.31 employees per reported executive. Evaluation of AgeX Therapeutics' management performance can provide insight into the firm performance.
Michael West  CEO
Chief Executive Officer, Founder, Director
Alfred Kingsley  Chairman
Chairman of the Board
  
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

AgeX Therapeutics Management Team Effectiveness

The company has Return on Asset of (0.8188) % which means that on every $100 spent on assets, it lost $0.8188. This is way below average. AgeX Therapeutics' management efficiency ratios could be used to measure how well AgeX Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.

AgeX Therapeutics Workforce Comparison

AgeX Therapeutics is rated below average in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 2,017. AgeX Therapeutics adds roughly 4.0 in number of employees claiming only tiny portion of equities under Health Care industry.

AgeX Therapeutics Insider Trading

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific AgeX Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on AgeX Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, AgeX Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

AgeX Therapeutics Notable Stakeholders

An AgeX Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as AgeX Therapeutics often face trade-offs trying to please all of them. AgeX Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting AgeX Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Michael WestChief Executive Officer, Founder, DirectorProfile
Alfred KingsleyChairman of the BoardProfile
Aubrey GreyVice President - New Technology DiscoveryProfile
Andrea ParkChief Financial OfficerProfile
Michael MayIndependent DirectorProfile
EunJae CPAChief OfficerProfile
Judith SegallSecretaryProfile
Gregory BaileyIndependent Chairman of the BoardProfile
Ivan LabatChief Information OfficerProfile
Joanne HackettInterim BoardProfile
Hal SternbergVice President - ResearchProfile
Nafees MDChief OfficerProfile
Annalisa JenkinsIndependent DirectorProfile

About AgeX Therapeutics Management Performance

The success or failure of an entity such as AgeX Therapeutics often depends on how effective the management is. AgeX Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of AgeX management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the AgeX management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. AgeX Therapeutics, Inc. was incorporated in 2017 and is based in Alameda, California. Agex Therapeutics operates under Biotechnology classification in the United States and is traded on AMEX Exchange. It employs 5 people.
Please note, the presentation of AgeX Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, AgeX Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of AgeX Therapeutics' management manipulating its earnings.

AgeX Therapeutics Workforce Analysis

Traditionally, organizations such as AgeX Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare AgeX Therapeutics within its industry.

AgeX Therapeutics Manpower Efficiency

Return on AgeX Therapeutics Manpower

Revenue Per Employee35.5K
Revenue Per Executive10.9K
Net Loss Per Employee3.7M
Net Loss Per Executive1.1M
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.
You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.

Other Consideration for investing in AgeX Stock

If you are still planning to invest in AgeX Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the AgeX Therapeutics' history and understand the potential risks before investing.
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Share Portfolio
Track or share privately all of your investments from the convenience of any device
CEOs Directory
Screen CEOs from public companies around the world
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing